PAR 2.17% 23.5¢ paradigm biopharmaceuticals limited..

Potential Financial Implications of Yesterday's Results, page-76

  1. 1,216 Posts.
    lightbulb Created with Sketch. 1375
    Costs for the API won't be much different to what J&J secure it for on a per kg basis.

    @Kiwinvestor not a typo. PAR are taking all the risks and have funded all of the programs themselves, and the profit margin is probably greater than 90%. If proven to be DMOAD it'll be 1st on the treatment algorithm so iPPS will effectively market itself, very little work required. If PAR carry the product through to registration without a licensing deal or any other deal, then there's no way a deal will be made for a 25% or 35% royalty. There will be very little risk for any distributor, aside from potential competitor or IP or generic risks.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.5¢
Change
0.005(2.17%)
Mkt cap ! $82.20M
Open High Low Value Volume
23.5¢ 23.5¢ 23.0¢ $85.35K 365.1K

Buyers (Bids)

No. Vol. Price($)
10 280011 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
24.0¢ 44703 3
View Market Depth
Last trade - 16.10pm 06/09/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.